N-Formyl peptide receptors (FPRs: FPR1, FPR2, and FPR3) are G protein-coupled receptors that play key roles in modulating immune cells. FPRs represent potentially important therapeutic targets for the development of drugs that could enhance endogenous anti-inflammation systems associated with various pathologies, thereby reducing the progression of inflammatory conditions. Previously, we identified 2-arylacetamide pyridazin-3(2H)-ones as FPR1-or FPR2-selective agonists, as well as a large number of FPR1/FPR2-dual agonists and several mixed-agonists for the three FPR isoforms.
Introduction
Human formyl peptide receptors (FPR1, FPR2, and FPR3) are a family of versatile Gprotein-coupled receptors (GPCRs) that represent attractive therapeutic targets because of their involvement in a wide range of normal physiological processes, as well as pathological events associated with inflammatory conditions [1] [2] [3] [4] . Originally identified in phagocytic leucocytes, FPRs mediates chemotaxis and activation of the majority of immune system cells in response to bacterial products and various inflammatory stimuli [3] . However, recent studies indicate that FPRs are also expressed in a variety of nonhematopoietic cells, such as lung epithelial cells, platelets, osteoblasts, and hepatocytes, suggesting a wider role for FPRs beyond inflammation and host defense [5] .
FPR activation can induce pro-or anti-inflammatory responses, depending on the nature of the ligand and cell types involved. For example, FPRs have been reported to contribute to inflammation associated with amyloidosis and Alzheimer's disease, prion disease, human immunodeficiency virus, stomach ulcer, some cancers, nociception associated with inflammatory processes, chronic obstructive pulmonary disease (COPD), stroke and ischemia-reperfusion injury [6] [7] [8] [9] [10] [11] [12] [13] . Conversely, stimulation of FPRs with certain agonists can also induce pro-resolving responses or endogenous anti-inflammatory systems [3] . Indeed, screening of commercial libraries and new synthetic compounds has resulted in the discovery of a number of small-molecule nonpeptide FPR agonists and antagonists with a wide range of chemical diversity and activities [14] [15] [16] .
In previous studies, we identified several pyridazin-3(2H)-one-based derivatives that showed an interesting profile as FPR agonists, combining an appreciable potency and differential selectivity toward the three human FPR isoforms [17] [18] [19] [20] [21] . Key requirements for agonist activity of this class of compounds were the presence of a 4-bromophenylacetamide side chain at the N-2 position of the scaffold [17, 19] and the presence of a methyl group at C-6 [20] . Position 4 could be substituted with a benzyl or phenylamino group, resulting in compounds with micromolar activity In the present study, we further investigated pyridazinone derivatives belonging to the series of 4-phenylamino derivatives (structure A, X = NH) which until now was only poorly studied [20] .
In particular, we inserted at position 5 of the pyridazinone scaffold a variety of substituents, such as alkyl or acyl groups, ester, unsaturated chains, and pyrazole rings, in order to evaluate how such modifications affected target specificity and compound potency.
Chemistry
All compounds were synthesized as reported in Schemes 1-5, and the structures were confirmed using analytical and spectral data.
The synthetic pathway leading to the final compounds 6a-f bearing an acyl group at position 5 is outlined in Scheme 1. Previously described isoxazolo-pyridazinones of type 1 [22] [23] [24] [25] were transformed into the corresponding 4-amino-5-acetyl derivatives 2a-f (2a-d [25] ) by reductive cleavage with 10% Pd/C and HCOONH 4 in ethanol. The products were then converted to the 4-bromophenylacetamide derivatives 5a-f as follows. Intermediates 2a and 2d,e were alkylated with ethylbromoacetate under standard conditions to generate 3a [20] and 3d,e, which were transformed into the corresponding carboxylic acids 4a [22] and 4d,e through alkaline hydrolysis. These were transformed into the final amides of type 5 by treatment with 4-bromoaniline, ethyl chloroformate and triethylamine in THF. Compounds 5b,c and 5f were obtained starting from their respective intermediates by a direct alkylation with N-(4-bromophenyl)-2-chloroacetamide [26] under standard conditions. Finally, a coupling reaction between 5a-f and 3-methoxybenzenboronic acid was carried out in the presence of copper(II)acetate and Et 3 Reagents and conditions: i) 10% Pd/C, HCOONH 4, anhydrous EtOH, reflux, 1 h; ii) ethyl bromoacetate, K 2 CO 3, anhydrous CH 3 CN, reflux, 2 h; iii) 6N NaOH, EtOH, 60 °C, 1 h; iv) Et 3 N, anhydrous THF, ethyl chloroformate, 4-bromoaniline, -5°C, rt and then 17.5 h; v) N-(4-bromophenyl)-2-chloroacetamide, K 2 CO 3, anhydrous CH 3 CN, reflux, 2 h; vi) 3-methoxybenzenboronic acid, (CH 3 COO) 2 Synthetic routes used to obtain the 5-alkyl (11a-d) and 5-vinyl (13) derivatives are shown in Scheme 2. Intermediates 2a-d [25] were converted to the desired final compounds 11a-d through the following steps: reduction of the acetyl at C-5 with NaBH 4 (compounds 7a-d), dehydratation with polyphosphoric acid (PPA) (8a-d), reduction of the vinyl group with a Parr instrument (9a-d),
insertion of the fragment at N-2 (10a-d), and coupling with 3-methoxybenzeneboronic acid (11a-d).
To obtain the final compound 13, direct alkylation with N-(4-bromophenyl)-2-chloroacetamide [26] on intermediate 8a was performed (compound 12), followed by a coupling reaction with 3-methoxybenzenboronic acid. Reagents and conditions: i) Et 3 N, MeOH or EtOH, 60°C, 4 h; ii) N-(4-bromophenyl)-2-chloroacetamide, K 2 CO 3, anhydrous CH 3 CN, reflux, 2-4 h; iii) 3-methoxybenzenboronic acid, (CH 3 COO) 2 Cu, Et 3 N, anhydrous CH 2 Cl 2, rt, 16 h; iv) 2N NaOH, EtOH, rt, 1 h.
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The pyrazolyl derivatives 25a,b were obtained following the procedures outlined in Scheme 4. Compound 19 [22] was transformed into the intermediated 20, as previously reported, and then was condensed with N,N-dimethylformamide dimethyl acetal to obtain derivative 21.
Treatment with Mo(CO) 6 [28] led to 22. Condensation with hydrazine hydrate gave the C-5 pyrazolyl pyridazinone 23 which, in turn, was alkylated with iodomethane (compound 24) and coupled with 3-methoxybenzenboronic acid (25a,b). Reagents and conditions: i) Et 3 N, anhydrous THF, ethyl chloroformate, 4-bromoaniline, -5°C and then rt, 17.5 h; ii) DMF/DMA, 90°C, 3 h; iii) Mo(CO) 6 Finally Scheme 5 describes the synthetic pathway leading to the final 5-unsubstituted pyridinone and pyridazinone derivatives 28a-b, which were obtained starting from appropriate intermediates 26a [29] and 26b [30] following the usual synthetic procedures described in previous schemes. Replacement of the ketone at C-5 (Table 1) Activities of the 5-alkyl derivatives 13a-d are presented in Table 2 . Compound 13a, in which R = C 2 H 5 , was the most potent of this series. It was active in the nanomolar range toward the three FPR subtypes but had a preference for FPR2 (EC 50 = 61 nM). Elongation of the aliphatic chain was detrimental for activity, resulting in compounds with micromolar EC 50 values for FPR1
Scheme 5
and FPR2 and no activity at FPR3. Surprisingly, the 5-propyl derivative 13b was completely devoid of activity. This is likely due to the loss of H-bonding between this compound and the receptor (see molecular modeling details below). Furthermore, elimination of the C-5 substituent led to a compound 29a with high nanomolar agonist activity for FPR1 (EC 50 = 0.24 M). Finally, compound 29b exhibited moderate mixed agonist activity for FPR1 and FPR2, but was one order of magnitude lower in activity than 29a at FPR1, suggesting that the pyridonic scaffold was less appropriate compared with the pyridazinone scaffold. [a] Values, expressed as EC 50 (µM) and Efficacy (% in brackets) were evaluated in a Ca 2+ flux assay. EC 50 values represent the average mean of three independent experiments and were determined by nonlinear regression analysis of the concentration-response curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (p < 0.05). Efficacy (in brackets) is expressed as % of the response induced by 5 nM fMLF in human polymorphonuclear neutrophils (hPMN) and FPR1-HL60 cells or by 5 nM WKYMVm in FPR2-HL60 and FPR3-HL60 cells.
[b] N.A., no activity (no response was observed during first 2 min after addition of compounds under investigation) considering the limits of efficacy < 20% and EC 50 < 50 μM.
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[a] Values, expressed as EC 50 (µM) and Efficacy (% in brackets) were evaluated in Ca 2+ flux assay. EC 50 values represent the average mean of three independent experiments and were determined by nonlinear regression analysis of the concentration-response curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (p < 0.05). Efficacy (in brackets) is expressed as % of the response induced by 5 nM fMLF in human polymorphonuclear neutrophils (hPMN) and FPR1-HL60 cells or by 5 nM WKYMVm in FPR2-HL60 and FPR3-HL60 cells.
The most active derivatives (8a, 15 and 27a-b) were also evaluated for chemoattractant activity in human neutrophils. As expected for FPR agonists, all four compounds had chemoattractant activity and induced this response in the micromolar range (Table 3) . [a] The data are presented as the mean ± SD of three independent experiments with cells from different donors, in which median effective concentration values (EC 50 ) were determined by nonlinear regression analysis of the concentrationresponse curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (p < 0.05).
Some of the synthesized compounds were also evaluated for their ability to induce intracellular Ca 2+ flux in mouse neutrophils and RBL cells transfected with Fpr1 or Fpr2 ( Although all compounds tested were active in human neutrophils, only eight of these compounds activated Ca 2+ flux in mouse neutrophils. Of these, three compounds were also agonists for mouse Fpr1, mouse Fpr2, or both. The reason for this species-specific difference in activity is currently not understood; however, we and other group have observed quite different response patterns to some agonists and/or antagonists in human and mouse neutrophils [14] . Table 4 . Activity of pyridazinones in mouse neutrophils and mouse Fpr-transfected RBL cells.
Compd mPMN [a] mFpr1-RBL [a] mFpr2-RBL [a] 8a N.A. N.A. N.A. [b] 8c N.A.
[b]
N.A.
[b] 8e 15.9 ± 4.9 (120) N.A.
N.A. [b] 8f N.A.
N.A. [b] 19a N.A.
N.A. [b] 19b N.A.
N.A. N.A. N.A. [b] 27a N.A.
[b] 27b 6.0 ± 1.9 (80) 18.5 ± 4.1 (25) 18.3 ± 3.8 (35) [a] The EC 50 (µM) and Efficacy (% in brackets) were evaluated in Ca 2+ flux assay. Values are expressed EC 50 presented as the average mean of three independent experiments, in which EC 50 values were determined by nonlinear regression analysis of the concentration-response curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (p < 0.05). Efficacy (in brackets) is expressed as % of the response induced by 5 nM WKYMVm in mouse polymorphonuclear neutrophils (mPMN) or RBL cells transfected with mouse Fpr1 (mFpr1-RBL) or Fpr2 (mFpr2-RBL).
[b] N.A., no activity (no response was observed during first 2 min after addition of compounds under investigation) considering the limits of efficacy < 20% and EC 50 < 50 µM.
Molecular docking studies
Our data suggest that larger substituents at position 5 may cause steric hindrance and that the optimal length of this group was two carbon atoms. To evaluate the role of steric hindrance from bulky acyl groups, we performed molecular docking of compounds 8a and 8e into the binding site of an FPR1 homology model and compounds 13a-c into the binding site of an FPR2 homology model. With each of these pairs, the compounds differ in size of acyl or alkyl groups at position 5 of the pyridazine heterocycle.
As shown in Figure 2A , the best docking pose of 8a occupies areas of FPR1 characteristic of other FPR1 agonists [31] . For example, the p-bromo substituted aromatic ring of 8a is positioned near channel A, and the acetyl group enters cavity B (receptor regions designated as previously reported [31] ). Additionally, strong H-bonds form between the carbonyl oxygen and anilide nitrogen atoms of 8a and Thr265 of FPR1, whereas a weaker H-bond is formed between the methoxy substituent and Arg205 ( Figure 2B ). These interactions may contribute to the agonist activity of compound 8a. Close contact of the acetyl group in 8a and FPR1 Leu198 was observed for the calculated ligand-receptor complex ( Figure 2B ), and the shortest interatomic distance between the acetyl oxygen and hydrogen atom of Leu198 located at the wall of cavity C was ~2. A homology model of FPR2 was similarly used to perform molecular docking with 13a-c.
These molecules have quite subtle differences in structure and are oriented in the binding site with brominated benzene rings directed deep into the binding site ( Figure 3A ). This orientation of the pbromophenyl moiety is analogous to that observed previously for parent compounds [20] . Agonist 13a with an ethyl substituent at position 5 of the pyridazine ring is H-bonded with Thr177, while the m-methoxyphenyl substituent occupies a hydrophobic subpocket surrounded by Ala181, Gly264, Leu268, Tyr277, and Ile279 ( Figure 3B ). Changing the alkyl substituent from ethyl to nbutyl in compound 13c led to flipping of the molecule so that the butyl chain of this ligand was now located in the hydrophobic subpocket, while the m-methoxyphenyl group formed an H-bond with Asn171 ( Figure 3C ). For 13b, a flipped pose similar to 13c was obtained. However, the substituted pyridazine 13b did not form H-bonds with the receptor, which likely led to decreased affinity of the propyl derivative and complete lack of biological activity (see Table 2 ).
Figure 3
Thus, larger substituents in position 5 of the pyridazine heterocycle cause steric effects on the binding modes of the ligands in the FPR1 and FPR2 binding sites, which is consistent with their reduced or lost agonist activity.
Conclusions
We describe the synthesis of new series of C-5 substituted 2-arylacetamide pyridazin-3(2H)-ones that exhibit improved potency and selectivity toward FPR isoforms. Biological analysis of these compounds confirmed the suitability of pyridazinone-based compounds as a relevant system to develop novel human FPR agonists. Indeed, the majority of compounds described herein were mixed FPR agonists, with compounds 8a and 27b being the most potent (EC 50 values in the nanomolar range). Overall, we show that modification of position C-5 of the pyridazinone ring in 2-arylacetamide pyridazin-3(2H)-ones represents an effective approach for the development of active FPR agonists. These compounds represent valuable tools for studying FPR activation and signaling in inflammatory conditions.
Experimental section

Chemistry
Reagents and starting materials were obtained from commercial sources. Extracts were dried over Na 2 SO 4 , and the solvents were removed under reduced pressure. All reactions were monitored by thin layer chromatography (TLC) using commercial plates precoated with Merck silica gel 60 F- Yields refer to chromatographically and spectroscopically pure compounds, unless otherwise stated.
Compounds were named following IUPAC rules, as applied by Beilstein-Institut AutoNom 2000 (4.01.305) or CA Index Name. All melting points were determined on a microscope hot stage Büchi apparatus and are uncorrected. The identity and purity of intermediates and final compounds were determined through NMR analysis and TLC chromatography.
1 H NMR, 13 C NMR and NOESY spectra were recorded with Avance 400 instruments (Bruker Biospin Version 002 with SGU).
Chemical shifts (δ) are reported in ppm to the nearest 0.01 ppm (for 1 H NMR) or 0.1 ppm (for 13 C NMR), using the solvent as an internal standard. Coupling constants (J values) of 1 H NMR are given in Hz and were calculated using 'TopSpin 1.3' software rounded to the nearest 0.1 Hz.
Microanalyses were performed with a Perkin-Elmer 260 elemental analyzer for C, H, and N, and the results were within ± 0.4 % of the theoretical values, unless otherwise stated.
General procedures for 2e and 2f
Ammonium formate (3.11 mmol) and 10% Pd/C (0.05 mmol) were added to a solution of the appropriate intermediate 1e and 1f [22] [23] [24] (1.04 mmol) in 5 mL of anhydrous EtOH, and the reaction was refluxed for 1 h. After cooling, 20 mL of CH 2 Cl 2 were added to the mixture, and the precipitate was removed by filtration under vacuum. The organic layer was then evaporated, and the desired products 2e,f were obtained pure after recrystallization from EtOH. 
General procedures for 3d and 3e
To a solution of the appropriate substrate 2d [25] and 2e (1.60 mmol) in anhydrous CH 3 CN (5 mL), K 2 CO 3 (3.20 mmol) and ethyl bromoacetate (2.40 mol) were added. The solution was stirred for 2-3 h at reflux, and the solvent was evaporated. The residue was mixed with ice-cold water (10 mL) and the precipitate was recovered by suction and recrystallized from ethanol (compound 3d); alternatively, for compound 3e, the suspension was extracted with CH 2 Cl 2 (3 x 15 mL) and the organic layer was dried over Na 2 SO 4 and evaporated in vacuo. Finally, 3e was purified by column flash chromatography using cyclohexane/ethyl acetate 1:1 as eluent. 
(5-Amino-3-methyl-6-oxo-4-pentanoylpyridazin-1(6H)-yl)acetic acid ethyl ester, 3d.
Yield = 97%; mp = 92-94 °C (EtOH
General procedures for 4d and 4e
To a solution of the suitable ester 3d and 3e (0.49-0.58 mmol) in 96% EtOH (5 mL), 6N NaOH (3 mL) was added. The reaction was carried out at 60°C for 1-2 h. After evaporation of the solvent, the mixture was diluted with ice-cold water, acidified with 6N HCl, and extracted with desired final compounds, which were purified by crystallization from ethanol. 
General procedures for 5a, and 5d-e
To a cooled (-5 °C) and stirred solution of the appropriate substrate 4a, 4d-e (4a [22] ) (0.98 mmol) in anhydrous tetrahydrofuran (5 mL), Et 3 N (3.43 mmol) was added. After 0.5 h, the mixture was allowed to warm up to 0 °C, and ethyl chloroformate (1.02 mmol) was added. After 1 h, 4-bromoaniline (1.96 mmol) was added. The reaction was carried out at room temperature for 16 h.
The mixture was then concentrated in vacuo, diluted with cold water (20-30 mL), and extracted with CH 2 Cl 2 (3 x 15 mL). The organic layer was dried over Na 2 SO 4 and evaporated to obtain crude final compounds, which were purified by crystallization from ethanol for compound 5a and by column flash chromatography using cyclohexane/ethyl acetate 1:1 as eluent, followed by recrystallization from EtOH, for compounds 5d and 5e. 
General procedures for 5b,c, 5f
A mixture of the appropriate intermediate 2b-c or 2f (0.96 mmol), K 2 CO 3 (1.93 mmol) and [26] (0.96-1.20 mmol) in CH 3 CN (10-15 mL) was refluxed under stirring for 2-6 h. The mixture was then concentrated in vacuo, and ice cold water was added.
N-(4-bromophenyl)-2-chloroacetamide
After 1 h stirring in an ice-bath, the precipitate was recovered by suction to obtain pure compound 5b-c. For compound 5f further purification was performed by column chromatography using cyclohexane/ethyl acetate 1:2 as eluent. 
General procedures for 6a-f
To were added, and the mixture was stirred at room temperature for 16 h. The suspension was extracted with 15% aqueous ammonia (3 x 10 mL), and the organic layer was washed with water (10 mL) and dried over Na 2 SO 4 . After removal of the solvent in vacuo, the final desired compounds were purified by column flash chromatography using as eluent CH 2 Cl 2 /MeOH 98:2, for compounds 6b-f
and cycloexane/ethyl acetate 1:3 for compound 6a. Compounds 6d and 6e were further purified by recrystallization from cyclohexane. 
N-(4-Bromophenyl)-2-[4-butyryl-5-(3-methoxyphenylamino)-3-methyl-6-oxo
N-(4-Bromophenyl)-2-[5-(3-methoxyphenylamino)-3-methyl-6-oxo-4-pentanoyl
N-(4-Bromophenyl)-2-[4-cyclopentanecarbonyl-5-(3-methoxyphenylamino)-3-methyl-
6-oxopyridazin-1(6H)-yl
N-(4-Bromophenyl)-2-[4-cyclohexanecarbonyl-5-(3-methoxyphenylamino)-3-methyl-
6-oxopyridazin-1(6)-yl]acetamide, 6f. Yield = 34%; mp = 181-183 °C (EtOH
General procedures for 7a-d
To a cooled (0 °C) suspension of compounds 2a-d (1.20 mmol) in 5 mL of MeOH, NaBH 4 (3.59-7.18 mmol) was slowly added, and the mixture was stirred for 1 h at room temperature. After cooling, cold water was added (10 mL) and compound 7a was recovered by filtration under vacuum.
For compounds 7b-d the suspension was extracted with ethyl acetate (3 x 10 mL) and the organic layer was dried over Na 2 SO 4 and evaporated to obtain crude final compounds, which were purified by crystallization from ethanol. 
4-Amino-5-(1-hydroxyethyl)-6-methylpyridazin-3(2H)-
General procedures for 10a-d
Compounds 10a-d were obtained starting from 9a-d following the same procedure described for 5b-c and 5f. For compounds 10b-d the suspension was extracted with ethyl acetate (3x 15 mL); the organic layer was dried over Na 2 SO 4 and evaporated to give desired final compounds which were purified by column chromatography using cyclohexane/ethyl acetate 1:2 (for 10b and 10d) or cyclohexane/ethyl acetate 1:3 (for 10c) as eluents. 
2-(5-Amino-3-methyl-6-oxo-4-propylpyridazin-1(6H)-yl)-N-(4-bromophenyl
2-(5-Amino-3-methyl-6-oxo-4-pentylpyridazin-1(6H)-yl)-N-(4-bromophenyl)
acetamide, 10d. Yield = 75%; mp = 167-171 °C (EtOH 
General procedures for 11a-d
Compounds 11a-d were obtained starting from 10a-d following the same procedure described for 6a-f. The final desired compounds were purified by column chromatography using as 
N-(4-Bromophenyl)-2-[4-butyl-5-(3-methoxyphenylamino)-3-methyl-6-oxopyridazin-
2-(5-Amino-3-methyl-6-oxo-4-vinylpyridazin-1(6H)-yl)-N-(4-bromophenyl)acetamide,
12.
Compound 12 was obtained following the same procedure described for 5b-c, 5f starting from 8a, followed by purification with column flash chromatography using cyclohexane 
General procedures for 16a and 16b
Compounds 16a-b were obtained starting from 15a-b following the same procedure described for 5b-c, and 5f. 
General procedures for 17a and 17b
Compounds 17a-b were obtained starting from 16a-b following the same procedure described for 6a-f. The final desired compounds were purified by crystallization from ethanol, followed by column flash chromatography using CH 2 Cl 2 /MeOH 98:2 as eluent. To prepare 18, 0.12 mmol of 17a were suspended in 2N NaOH (2 mL), and the reaction was stirred for 1 h at room temperature. 
General procedures for 25a and 25b
Compounds 25a-b were obtained starting from 24 following the same general procedure described for 6a-f. After removal of the solvent in vacuo, compound 25a was obtained by crystallization from ethanol and preparative TLC using ethyl acetate as eluent. 
N-(4-
Isolation of human neutrophils
Blood was collected from healthy donors in accordance with a protocol approved by the Institutional Review Board at Montana State University. Neutrophils were purified from the blood using dextran sedimentation, followed by Histopaque 1077 gradient separation and hypotonic lysis of red blood cells, as previously described [33] . Isolated neutrophils were washed twice and resuspended in Hank's balanced salt solution (HBSS) without Ca 2+ and Mg 2+ (HBSS -). Neutrophil preparations were routinely > 95% pure, as determined by light microscopy, and > 98% viable, as determined by trypan blue exclusion.
Isolation of mouse neutrophils
Mouse bone marrow neutrophils were isolated from bone marrow leukocyte preparations, as described previously [34] . In brief, bone marrow leukocytes were flushed from tibias and femurs of and Use Committee at Montana State University.
Ca 2+ mobilization assay
Changes in intracellular Ca 2+ were measured with a FlexStation II scanning fluorometer using a FLIPR 3 calcium assay kit (Molecular Devices, Sunnyvale, CA) for human neutrophils and HL-60 cells, as described previously [35] . All active compounds were evaluated in wild-type HL-60
and RBL cells to verify that the agonists are inactive in non-transfected cells. Human neutrophils, percentage of negative control and were calculated as follows: (number of cells migrating in response to test compounds/spontaneous migration in response to control medium)×100. EC 50 values were determined by nonlinear regression analysis of the concentration-response curves generated using Prism 5 software.
Molecular modeling
We used the FPR1 and FPR2 homology models created previously [20, 36] . Both models are based on the crystal structure of the bovine rhodopsin receptor. Before docking, structures of compounds 8a, 8e, and 13a-c were built and optimized using HyperChem 7.0 software with the MM+ force field and saved in Tripos MOL2 format. The ligand structures were then imported into MVD with the options "Create explicit hydrogens", "Assign charges (calculated by MVD)", and "Detect flexible torsions in ligands" enabled. The molecules were docked into FPR1 and FPR2 using the search spaces as applied in our previous publications [20, 31] and with a rigid receptor structure. MolDock score functions were applied with 0.3 Å grid resolution. Ligand flexibility was accounted for with respect to torsion angles auto-detected in MVD. The "Internal HBond" option was activated in the "Ligand evaluation" menu of Docking Wizard. Thirty docking runs were performed for each molecule. The option "Return multiple poses for each run" was enabled, and the post-processing options "Energy minimization" and "Optimize H-bonds" were applied after docking. Similar poses were clustered at a RMSD threshold of 1 Å.
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